Literature DB >> 15915542

Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells.

Ingrid E Dumitriu1, Paramita Baruah, Marco E Bianchi, Angelo A Manfredi, Patrizia Rovere-Querini.   

Abstract

Dendritic cells (DC) are key components of innate and adaptive immune responses. Plasmacytoid DC (PDC) are a specialized DC subset that produce high amounts of type I interferons in response to microbes. High mobility group box 1 protein (HMGB1) is an abundant nuclear protein, which acts as a potent pro-inflammatory factor when released extracellularly. We show that HMGB1 leaves the nucleus of maturing PDC following TLR9 activation, and that PDC express on the plasma membrane the best-characterized receptor for HMGB1, RAGE. Maturation and type I IFN secretion of PDC is hindered when the HMGB1/RAGE pathway is disrupted. These results reveal HMGB1 and RAGE as the first known autocrine loop modulating the maturation of PDC, and suggest that antagonists of HMGB1/RAGE might have therapeutic potential for the treatment of systemic human diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15915542     DOI: 10.1002/eji.200526066

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  68 in total

Review 1.  Impaired clearance of apoptotic cells in germinal centers: implications for loss of B cell tolerance and induction of autoimmunity.

Authors:  Ziaur S M Rahman
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

2.  Damage-associated molecular patterns (DAMPs) in preterm labor with intact membranes and preterm PROM: a study of the alarmin HMGB1.

Authors:  Roberto Romero; Tinnakorn Chaiworapongsa; Zeynep Alpay Savasan; Yi Xu; Youssef Hussein; Zhong Dong; Juan Pedro Kusanovic; Chong Jai Kim; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2011-09-29

3.  Anti-RAGE antibody ameliorates severe thermal injury in rats through regulating cellular immune function.

Authors:  Xiao-mei Zhu; Yong-ming Yao; Li-tian Zhang; Ning Dong; Yan Yu; Zhi-yong Sheng
Journal:  Acta Pharmacol Sin       Date:  2014-08-25       Impact factor: 6.150

4.  Damage associated molecular pattern molecules.

Authors:  Michael T Lotze; Albert Deisseroth; Anna Rubartelli
Journal:  Clin Immunol       Date:  2007-04-30       Impact factor: 3.969

Review 5.  Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history.

Authors:  Patricia Fitzgerald-Bocarsly; Jihong Dai; Sukhwinder Singh
Journal:  Cytokine Growth Factor Rev       Date:  2008-01-11       Impact factor: 7.638

Review 6.  Translational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis.

Authors:  N Maugeri; P Rovere-Querini; M Baldini; M G Sabbadini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2009-03-20       Impact factor: 4.330

7.  Neuropeptide modulators of high mobility group box 1 secretion as potential therapeutic agents for severe sepsis.

Authors:  Mitchell P Fink
Journal:  Am J Pathol       Date:  2008-04-10       Impact factor: 4.307

8.  The Free Radical Scavenger NecroX-7 Attenuates Acute Graft-versus-Host Disease via Reciprocal Regulation of Th1/Regulatory T Cells and Inhibition of HMGB1 Release.

Authors:  Keon-Il Im; Nayoun Kim; Jung-Yeon Lim; Young-Sun Nam; Eun-Sol Lee; Eun-Jung Kim; Hyoung Jin Kim; Soon Ha Kim; Seok-Goo Cho
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

9.  RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes.

Authors:  Ana M Avalos; Kerstin Kiefer; Jane Tian; Sean Christensen; Mark Shlomchik; Anthony J Coyle; Ann Marshak-Rothstein
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

10.  Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia.

Authors:  Li Jia; Andrew Clear; Feng-Ting Liu; Janet Matthews; Nadiha Uddin; Aine McCarthy; Elena Hoxha; Catherine Durance; Sameena Iqbal; John G Gribben
Journal:  Blood       Date:  2014-01-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.